1. A PHASE 1/1B DOSE‐ESCALATION TRIAL EVALUATING CPI‐818, AN ORAL INTERLEUKIN‐2‐INDUCIBLE T‐CELL KINASE INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL LYMPHOMA. (12th June 2019) Authors: Mobasher, M.; Miller, R.; Janc, J.; Kwei, L.; Barker, C.; Mohammady, A.; Luciano, G.; Radeski, D.; Kim, Y.; Khodadoust, M.; Horwitz, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS. (17th June 2021) Authors: Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; Ganesan, N.; Sohail, S.; Santarosa, A.; Galasso, N.; Kim, E.; Myskowski, P.; Kim, Y. H.; Horwitz, S.; Moskowitz, A. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL). (12th June 2019) Authors: Collins, G.; Horwitz, S.; Hamadani, M.; Samaniego, F.; Spira, A.; Caimi, P.; Davies, A.; Menne, T.; Fields, P.; Cruz, H.; He, S.; Boni, J.; Feingold, J.; Wuerthner, J.; Radford, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. (June 2017) Authors: Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.; Portlock, C.S.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA. (12th June 2019) Authors: Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D.J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; Hamlin, P.; Zelenetz, A.; Matasar, M.; von Keudell, G.; Sermer, D.; Yahalom, J.; Dogan, A.; Seshan, V.; Younes, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. (June 2017) Authors: Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; Kumar, A.; Matasar, M.; Moskowitz, A.; Moskowitz, C.; Noy, A.; Palomba, M.; Portlock, C.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PATIENT‐REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. (June 2017) Authors: Prince, H.M.; Dummer, R.; Whittaker, S.; Horwitz, S.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.L.; Wolter, P.; Sanches, J.; Ortiz‐Romero, P.; Akilov, O.; Geskin, L.; Huen, A.; Wang, Y.; Palanca‐Wessels, M.C.; Richhariya, A.; Feliciano, J.; Zhu, Y.; Lin, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PB2121: EFFECT OF EDUCATIONAL ACTIVITY ON THE KNOWLEDGE OF CLINICIANS REGARDING THE LATEST CLINICAL TRIAL DATA INVESTIGATING NOVEL EPIGENETIC AGENTS FOR B- AND T-CELL LYMPHOMAS. (23rd June 2022) Authors: Harvey-Jones, V.; Koekkoek, S.; Dorkhom, N.; Horwitz, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1992 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA. (June 2017) Authors: Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; Moskowitz, A.; Zelenetz, A.; Ahsanuddin, S.; Callan, D.; Freidin, B.; Porzio, R.; Soiffer, J.; Copeland, A.; Dang, T.; Rademaker, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL LYMPHOMA: PHASE II RESULTS. (12th June 2019) Authors: Lunning, M.; Horwitz, S.; Advani, R.; Vose, J.; Lee, H.; Mehta‐Shah, N.; Zain, J.; Haverkos, B.; Lechowicz, M.; Moskowitz, A.; Heires, P.; Lyden, L.; Ansell, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 280 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗